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S U M M A R Y
Objectives: To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis
(TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment
(ART) along with rifampin-containing anti-TB treatment.
Methods: This was a nested study within a randomized clinical trial, taking place between May 2006 and
June 2008 at the National Institute for Research in Tuberculosis, Chennai, India. Antiretroviral-naı¨ve HIV-
infected TB patients were initiated on an intermittent short-course regimen and randomized to receive
didanosine and lamivudine with either NVP (400 mg) or EFV (600 mg) once-daily. Blood was analyzed
for alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum alkaline phosphatase (SAP),
and bilirubin at baseline, at ART initiation, fortnightly after ART initiation until 2 months, then monthly
until 6 months and 6-monthly thereafter.
Results: Of the 168 patients included (79% men, median CD4 count 93 cells/mm3, median viral load
242 000 copies/ml), 104 were on EFV-based ART and 64 on NVP-based ART. There was a small but
statistically signiﬁcant elevation in ALT and SAP at 2 weeks and AST at 6 weeks after ART initiation. The
proportion of patients with rate-limiting toxicity of liver enzymes was small. None had treatment
terminated because of hepatotoxicity.
Conclusion: Hepatotoxicity is not a major concern when HIV-infected TB patients, with normal baseline
liver function initiate treatment for both infections simultaneously.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
It is estimated that there are approximately 1.1 million adults
co-infected with HIV and tuberculosis (TB) globally.1 The World
Health Organization (WHO) recommends initiating antiretroviral
treatment (ART) for all HIV–TB co-infected patients within a few
weeks of TB treatment, regardless of CD4 cell count, to reduce all-
cause mortality and improve TB treatment outcomes.2,3 In a
public health approach, recommended ART regimens include
combinations of two nucleoside reverse transcriptase inhibitors
(NRTIs) and a non-nucleoside reverse transcriptase inhibitor
(NNRTI), with nevirapine (NVP) or efavirenz (EFV) being the* Corresponding author. Tel.: +91 44 2836 9586; fax: +91 44 2836 2525.
E-mail address: doctorsoumya@yahoo.com (S. Swaminathan).
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http://dx.doi.org/10.1016/j.ijid.2013.08.006preferred NNRTIs.2 For the treatment of TB, regimens containing
isoniazid and a rifamycin throughout are recommended, as they
have better outcomes in terms of lower failure and recurrence
rates.4,5
Although studies have reported clinical and virological efﬁcacy
with the concurrent use of NNRTI and rifamycin-based TB
treatment,6,7 few reports have been published on the safety of
the concomitant use of these regimens. Isoniazid, rifampin, NVP,
and EFV are all associated with hepatotoxicity, and little is known
about the relative rates of hepatotoxicity with either NVP or EFV in
the setting of rifampin-based TB treatment.8 Further, there is no
information on rates of hepatotoxicity among HIV–TB co-infected
patients treated with an intermittent (three times weekly)
regimen. Studies in HIV-uninfected populations suggest that
toxicity rates tend to be lower in patients given intermittent
compared to daily chemotherapy.9ses. Published by Elsevier Ltd. All rights reserved.
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(H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed
by 4 months of H and R given three times weekly throughout
(2EHRZ3/4RH3). ART is begun between 2 weeks and 2 months
following the initiation of anti-TB therapy (ATT), based on CD4 cell
counts, with a combination therapy of two NRTIs with one NNRTI,
EFV being the preferred drug for co-administration with rifampin.
However NVP is the most widely used NNRTI worldwide as it is
inexpensive, non-teratogenic, is available in ﬁxed drug combina-
tions, and can also be administered once-daily. No detailed
comparative data exist on the effects of these regimens on liver
enzymes.
We studied the changes in liver function during and after
treatment with rifampin-based ATT given along with once-daily
NNRTI-based ART, in adults with HIV–TB co-infection who
participated in a clinical trial in Tamilnadu, India (ClinicalTrials.-
gov; NCT00332306).
2. Methods
This study was part of a prospective randomized controlled
clinical trial ‘‘Efﬁcacy and safety of once-daily nevirapine- or
efavirenz-based antiretroviral therapy when co-administered with
rifampin-based antitubercular therapy’’, the details of which have
been described elsewhere.10 In brief, between May 2006 and June
2008, HIV-1-infected adults with active TB and a CD4 count 250
cells/mm3 were enrolled in a study at the National Institute for
Research in Tuberculosis (formerly the Tuberculosis Research
Centre). Patients with prior ART or ATT, an HIV-2 infection, or
serum aminotransferases >2.5 times the upper limit of normal
(ULN) were excluded. The ‘once-daily ART’ controlled clinical trial
collected detailed clinical and laboratory data to monitor the safety
and efﬁcacy of administering different ART regimens in combina-
tion with ATT. Therefore, it was possible to monitor the
development of hepatotoxicity at various time points in the trial.
All patients enrolled in the ‘once-daily ART’ study initiated a
standard TB treatment with four drugs: isoniazid (600 mg),
rifampin (450/600 mg based on body weight <60 or >=60 kg),
ethambutol (1200 mg), and pyrazinamide (1500 mg) for the ﬁrst 2
months; two drugs, isoniazid and rifampin, were used for the
subsequent 4 months. All drugs were administered three times
weekly (2EHRZ3/4RH3) under direct observation, in accordance
with national guidelines. After 2 months of TB treatment,
participants were randomized to the once-daily ART regimen
(month 0) with either NVP (400 mg, after a lead-in period of
200 mg once-daily) or EFV (600 mg per day), along with didanosine
(250/400 mg for body weight <60 or 60 kg) and lamivudine
(300 mg).
The time of ATT initiation was deﬁned as ‘baseline’ and the time
of ART initiation (i.e., 2 months after ATT initiation) as month 0.
Subsequent weeks/months are chronological with reference to
month 0 throughout this article. ART was administered under
direct supervision 3 days per week and supplied to the patient for
self-administration on the remaining days. ATT was stopped at 6
months and ART was continued (Figure 1).
Liver function tests including alanine aminotransferase (ALT),
aspartate aminotransferase (AST), serum alkaline phosphatase
(SAP), and bilirubin were measured using an automated analyzer
(Olympus AU400, Japan) at baseline (month 2), month 0, then
every 2 weeks until week 8 (month 2) and then once every 8 weeks
until 6 months. Hepatotoxicity grades were deﬁned in accordance
with the AIDS Clinical Trials Group (ACTG) criteria: grade I, 1.25–
2.5 times ULN; grade II, 2.5–5.0 times ULN; grade III, 5–10 times
ULN; grade IV, >10 times ULN.11 Mild hepatotoxicity was deﬁned
as ACTG grades I and II, and severe toxicity as grades III and IV.2.1. Statistical analysis
The distribution of each variable was checked cross-sectionally
at baseline and follow-up. All unusual values were veriﬁed. Mean
values and standard deviations were tabulated for normally
distributed variables; the median and 25th and 75th percentiles
were tabulated for skewed variables. We compared baseline liver
enzymes and various baseline demographic and clinical char-
acteristics between treatment groups using the Student’s t-test or
the Wilcoxon rank-sum test, as appropriate. Changes in liver
enzymes during both the early and late stage of treatment were
compared with baseline levels using repeated measures analyses,
with skewed variables transformed to attain normality. We also
compared changes in liver enzymes between treatment groups
using the Mann–Whitney U-test. We compared the proportion of
patients with liver enzyme abnormalities at baseline vs. at 12
months using the McNemar test for correlated proportions and the
Chi-square test to compare between the two treatment groups. All
tests used a = 0.05 as the cut-off for statistical signiﬁcance.
Analyses were performed using SPSS software version 14.0 (SPSS
Inc., Chicago, IL, USA).
The study was approved by the ethics committee of the
National Institute for Research in Tuberculosis, and informed
written consent was obtained from all patients prior to study
enrollment.
3. Results
Of the 179 patients enrolled into the once-daily ART study, 168
patients (132 men, 36 women) were found eligible for the current
analysis (11 were not randomized – early drop-outs). Follow-up
data were available for 157 patients at 4 months, 151 at 6 months,
and 140 patients at 12 months (15 patients died, 11 were lost to
follow-up, and two missed study visits) (Figure 1).
3.1. Patient characteristics
At baseline, the 168 HIV-infected patients with TB (79% men)
had a mean age of 36 years, mean body weight of 42 kg, a median
CD4 count of 93 cells/mm3, and HIV viral load of 242 000 copies/ml.
One hundred and four patients were randomized to the EFV arm
and 64 to the NVP arm (the data safety monitoring board stopped
the intake of patients into the NVP arm after the ﬁrst interim
analysis, which explains the unequal numbers). At baseline,
patients did not differ signiﬁcantly between the two treatment
arms with respect to body weight, CD4 cell count, or viral load
(Table 1). Forty-four percent of patients consumed alcohol (often
or habitually) and 2.4% had a hepatitis co-infection (hepatitis B in
three patients, hepatitis C in one patient). None of the patients in
our study population had a hepatitis B and C co-infection. Drug
intake was directly observed 3 days a week and overall adherence
was >90%. The majority of subjects had an undetectable HIV load
after 12 months of ART.
3.2. Baseline liver enzymes
Baseline liver enzymes were comparable in the two treatment
groups. AST and ALT were signiﬁcantly higher among patients with
CD4 counts <90 cells/mm3 (54 vs. 41 mg/dl, p < 0.002, and 35 vs.
27 mg/dl, p = 0.01, respectively), while SAP was higher among
patients with a viral load >300 000 (249 vs. 171 mg/dl, p = 0.04).
These cut-offs were based on the median levels at baseline.
At baseline, ALT was >100 mg/dl in three patients (2%), AST was
>100 mg/dl in seven patients (6%), and SAP was >350 mg/dl in 18
patients (12%); these patients were excluded from the analysis.
Month 0 
n = 168 
Month 4 
n = 157
Month 6 
n = 151 
Screen patients 
Admit eligible HIV–TB patients to study and 
start on EHRZ3 (Baseline n = 179)
After 2 months intensive phase, randomize to  
ART regimen and switch to RH3
(Clinical exam, LFT, CD4 and VL) 
11 drop outs 
ATT + NVP/ddI/3TC 
n = 64 
ATT + EFV/ddI/3TC 
n = 104 
Stop ATT: Month 4 
Continue ART 
Stop ATT: Month 4 
Continue ART 
Clinical and LFT monitoring every 2 
weeks for 8 we eks, then  4-weekly 
until 6 months
ART alone: Month 6 ART alone: Month 6 
Clinical, LFT 
End of study: Define Outcomes 
Clinical exam, LFT, CD4 and VL 
(Month 12,  n = 140) 
Figure 1. Schematic diagram of the ‘once-daily ART’ study design.
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3.3.1. Effect of ATT alone
After 2 months of ATT, there was an increase in the median
values of liver enzymes, although this was not statistically
signiﬁcant (ALT 26 vs. 27 mg/dl, p = 0.71, and AST 41 vs. 42,Table 1
Baseline characteristics of the study populations of the two treatment groupsa
Variables at baseline Patients on EFV-based regimen (n = 104)
Age (years) 35 (6.9) 
Weight (kg) 41.9 (7.9) 
Male gender 81 (78%) 
Alcohol consumption (often) 43 (41%) 
CD4 count (cells/mm3) 90 (53–130) 
Viral load (copies/ml) 259 000 (81 200–531 000) 
AST (U/l) 43 (29–65) 
ALT (U/l) 26 (16–42) 
SAP (U/l) 127 (91–232) 
Serum bilirubin (mg/dl) 0.4 (0.3–0.5) 
EFV, efavirenz; NVP, nevirapine; AST, aspartate aminotransferase; ALT, alanine aminotran
range.
a Results are mean (SD), n (%), or median (IQR). Comparison between groups: t-test p = 0.69). These rises were minimal (less than two times ULN), and
ART was initiated.
3.3.2. Effect of ART and ATT together
At 2 weeks of ART, ALT increased from 26 to 32 mg/dl (p = 0.03)
and at 6 weeks AST from 41 to 46 mg/dl (p = 0.02). These increases Patients on NVP-based regimen (n = 64) p-Value
38 (1.7) 0.06
43 (7.7) 0.89
51 (80%) 0.78
31 (48%) 0.14
75 (34–130) 0.14
203 000 (87 900–370 000) 0.79
47 (29–52) 0.93
31 (19–41) 0.94
211 (74–260) 0.78
0.4 (0.3–0.5) 0.26
sferase; SAP, serum alkaline phosphatase; SD, standard deviation; IQR, interquartile
for means, and Wilcoxon signed rank test for medians.
Table 2
Pattern of change in liver enzymes on co-administration of once-daily NNRTI-based ART with rifampin-based ATTa
Liver enzymes
(normal range)
Baseline
(n = 168)
(No ATT/ART)
0 week
(n = 168)
(2 months
ATT + no ART)
2 weeks
(n = 157)
(ATT + ART)
1 month
(n = 161)
(3 months
ATT + 1
month ART)
6 weeks
Median (IQR)
(n = 133)
2 months
(n = 159)
(4 months
ATT + 2
months ART)
4 months
(n = 157)
(6 months
ATT + 4
months ART)
6 months
(n = 151)
(no ATT + 6
months ART)
12 months
(n = 140)
(no ATT + 12
months ART)
ALT (U/l) 26 27 32b 32 33 31 31 30 29
(5–41 U/l) (17–41) (21–36) (23–44) (24–53) (24–51) (24–43) (23–40) (22–46) (20–40)
AST (U/l) 41 42 43 43 46b 42 39 40 34
(5–40 U/l) (29–60) (33–54) (33–57) (34–60) (36–60) (32–54) (32–53) (30–52) (27–46)
SAP (U/l) 131 131 150 172 169 166 157 171b 143
(35–140 U/l) (85–238) (99–203) (98–250) (111–297) (118–275) (119–269) (118–226) (124–233) (107–176)
Serum bilirubin 0.4 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4
(mg/dl) (0.3–0.6) (0.3–0.4) (0.2–0.4) (0.2–0.4) (0.3–0.4) (0.3–0.5) (0.3–0.5) (0.3–0.5) (0.3–0.5)
(0.2–1.0 mg/dl)
NNRTI, non-nucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy; ATT, anti-tuberculosis therapy; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; SAP, serum alkaline phosphatase; IQR, interquartile range.
a All values are median (IQR). Comparison between time-points was done by repeated measure analysis.
b p < 0.005 was considered signiﬁcant.
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4 months of ATT given along with ART, a statistically signiﬁcant
rise in ALT was noticed (31 vs. 26 mg/dl, p = 0.001), but this was
also within normal limits. The increase in SAP at 8 weeks was to a
level slightly above normal and was also statistically signiﬁcant
(166 vs. 131 mg/dl, p = 0.001) (Table 2).
There were two cases of grade III hepatotoxicity (liver enzyme
elevation along with clinical jaundice) in the EFV arm, 1 month
after initiating ART (third month of ATT). ATT was changed to non-
hepatotoxic drugs and ART was temporarily withheld. The patients
were managed symptomatically with liver supportive supple-
ments (Liv.52 tablets), and after hepatotoxicity had subsided, ART
was reintroduced without further toxicity.
After 6 months, ATT was stopped (i.e., month 4 of ART) and only
ART continued. At this point, there was no signiﬁcant change in
liver enzymes from before.
At month 12 of ART (6 months after stopping ATT), AST and SAP
declined signiﬁcantly as compared to their month 4 levels (34 vs.
39, p = 0.01, and 143 vs. 157, p = 0.001, respectively). The ALT levels
were comparable (29 vs. 31, p = 0.44) (Table 2).
At 12 months, there was a signiﬁcant reduction in the
proportion of patients showing SAP >350 mg/dl. Repeated
measure analysis for 140 patients did not show any signiﬁcant
change in AST or ALT levels over 12 months (data not shown).
3.4. Changes in liver enzyme levels by type of ART regimen
During the early stage of treatment, there was a signiﬁcant
change in AST level in the EFV arm when ATT was given along withTable 3
Pattern of change in serum liver enzymes during treatment, categorized by the type o
Liver enzyme Change in liver enzymes at different time-points in the study – re
Levels at
0 week (mg/dl)
Change at
2 weeks
Change at
1 month
AST EFV (n = 100) 41 6.7 (32)a 1.0 (29) 
NVP (n = 60) 43 2.3 (26) 10.9 (89) 
p-Value - 0.05 0.84 
ALT EFV (n = 100) 27 9.5 (30) 9.8 (28) 
NVP (n = 60) 28 4.2 (19) 17.9 (99) 
p-Value - 0.12 0.26 
SAP EFV (n = 100) 134 45 (107) 56 (119) 
NVP (n = 60) 126 8.5 (46) 39 (116) 
p-Value - 0.01 0.40 
NNRTI, non-nucleoside reverse transcriptase inhibitor; ART, antiretroviral therapy; SD, st
ALT, alanine aminotransferase; SAP, serum alkaline phosphatase.
a p < 0.05, Mann–Whitney U-test, used for comparisons between regimens at the sam
NVP arm. Similarly, AST and ALT at 6 months in the NVP arm were signiﬁcantly differART, while in the NVP arm the change was noted both in AST and ALT
later, by 6 months (Table 3). Subsequently, the levels showed a trend
to decline. The proportion of patients with ALT or AST >100 mg/dl at
12 months was not different between the two arms (3% vs. 2%).
4. Discussion
In this study, the initiation of ATT led to an expected but not
signiﬁcant increase in liver enzyme levels. Co-administration of
ART with ATT was associated with elevated ALT during the early
phase of treatment; however these elevations were mild, not
associated with severe or rate-limiting toxicity, and decreased over
time. Similar results were also observed among the Home-Based
AIDS Care cohort of Uganda, where modestly elevated hepatic
aminotransferases were common before starting ART and during
co-administration of ART with TB treatment when measured at 3
months; however these elevations were not associated with severe
toxicity and no patients were excluded from the study on the basis
of severely elevated aminotransferases.12 Moreover, similar to the
ﬁndings of our group, the prevalence of elevated hepatic
aminotransferases in this cohort also declined at periodic
examinations during 2 years of treatment with ART.
The association of liver enzyme elevation and hepatic toxicity
with ATT when co-administered with ART is not unexpected, since
drug-induced hepatitis is a common complication of TB therapy
and may be due to the initial induction of liver enzymes by
rifampin. However, previous studies have also reported low rates
of hepatotoxicity when ART is administered along with rifam-
pin.8,13 Moses et al. reported 1.3% of grade II and <1% of grade IIIf NNRTI-based ART regimen
gimen wise, mean (SD)
Change at
6 weeks
Change at
2 months
Change at
4 months
Change at
6 months
Change at
12 months
3.0 (23) 0.3 (27) 5.2 (36) 6.8 (35) 0.3 (26)
5.7 (37) 0.6 (29) 3.1 (25) 7 (31)a 0.6 (29)
0.42 0.56 0.10 0.01 0.56
9.0 (26) 5.9 (28) 2.6 (29) 2.8 (31) 1.8 (32)
12.9 (39) 4.4 (23) 8.5 (30) 14.3 (33)a 13.6 (37)a
0.85 0.56 0.24 0.01 0.04
70 (123) 55 (145) 17 (148) 31 (196) 15 (118)
48 (144) 4.5 (130) 43 (108) 40 (104) 3 (84)
0.55 0.85 0.48 0.97 0.93
andard deviation; EFV, efavirenz; NVP, nevirapine; AST, aspartate aminotransferase;
e time-point, i.e. AST at 2 weeks in the EFZ arm was signiﬁcantly higher than in the
ent from enzymes at 6 months in the EFZ arm.
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(incidence rate 4.2/10 years of follow-up).13 In the Botswana
cohort of 155 patients on ART, while more hepatotoxic events
occurred in the group exposed to TB treatment than in those not
exposed (9% vs. 3%, p = 0.05), there was no difference between
patients treated with NVP and those treated with EFV.8 Failure to
see a signiﬁcant change in liver enzymes when ATT was co-
administered with NVP-based ART is a positive ﬁnding of our
study. In fact, the proportion of patients with grade II hepatotox-
icity was no different between the EFV and NVP arms. This is an
important ﬁnding for resource-limited countries where there is
high prevalence of TB and HIV, laboratory facilities are limited, and
NVP-based ART regimens are the most economical. The data from
this study are reassuring in that both the baseline and ‘on
treatment’ incidence of ALT elevations was very low and did not
complicate patient management or safety. Our ﬁndings are the ﬁrst
from India and also the ﬁrst using a once-daily NVP regimen with
concomitant rifampin-based ATT. A Spanish study on the co-
administration of rifampin and NVP in HIV–TB co-infected patients
also showed that the development of liver toxicity or skin rash was
no higher for the combination than when the drugs were given
separately.14 However, as reported previously, the virological
efﬁcacy of once-daily NVP-based ART given along with ATT was
signiﬁcantly lower in our trial and therefore this combination is
not a preferred option.15
The magnitude and rate of transaminitis that we observed in
our cohort appears low compared with that of other published
reports.16–18 However direct comparisons are difﬁcult to make
since deﬁnitions of elevated aminotransferases vary, ranging from
>2.0 to >5.0 times ULN. The Uganda study, using the same level of
aminotransferases as in our study (>2.5 times ULN) had a greater
number of patients with elevated aminotransferases at baseline
(38 vs. 7). However, by the end of 12 months the number of
patients with abnormal aminotransferases was almost the same as
in our study (grade II: 8 vs. 6).12
Earlier studies have suggested a greater risk of the development
of hepatotoxicity among patients with low CD4 cell counts, high
viral loads, and older age.19–21 In our group, patients with
advanced immunosuppression had modestly elevated amino-
transferases at baseline. Although the number of patients in this
group was small, we observed that the development of hepato-
toxicity had a statistically signiﬁcant association with immuno-
suppression of the patients as measured by CD4 cell counts. One
reason could be that patients with low CD4 cell counts are more
prone to acquire opportunistic infections, necessitating consump-
tion of different drugs, leading to subclinical liver damage and
thereby increasing susceptibility to hepatotoxicity. However since
this was a sub-study to a drug efﬁcacy trial, patients with elevated
aminotransferases (>2.5 times ULN) were excluded from enroll-
ment, hence the patient population was a selected one.
Our ﬁndings should be interpreted in the context of a few
limitations. Firstly patients had to fulﬁll several inclusion and
exclusion criteria to be eligible for the trial. Hence baseline liver
function was mostly in the normal range. Patients with severe pre-
existing liver or renal disease were excluded. Also, we did not have
a comparison group of patients with only HIV infection on ART,
which would have helped us to determine the additive effect of
ATT on liver enzymes when co-administered with ART. Further, the
median CD4 cell count of the participants in the present analysis
was well below the values that have been associated with an
increased risk of NVP-associated hepatotoxicity in developed
countries. Since NVP is a common cause of transaminitis that may
resolve even with continuation of antiretrovirals, any further rise
after the initial close monitoring may have gone unnoticed.22 Last,
we did not look for an interaction with alcohol at the individual
level and hepatitis B/C co-infection was rare. In previous cohortsfrom the same region, the prevalence of HIV–hepatitis B virus co-
infection varied from 6% to 9%, and of HIV–hepatitis C virus co-
infection from 2% to 3%.23,24 So these co-infections are rare in this
population.
In summary, HIV–TB patients treated with an intermittent anti-
TB regimen and once-daily NNRTI-based ART regimen did not
experience signiﬁcant changes in liver function over 12 months.
Minimal elevation of aminotransferases occurred, but was
transient, improved after completion/discontinuation of ATT,
and was not worse with NVP than EFV. Hepatotoxicity was rare
in this group of patients with normal liver function at baseline and
low rates of hepatitis B/C co-infection.
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